Business Context and Reporting Period
This Form 8-K is filed by Diamedica Therapeutics Inc. (DMAC) on August 12, 2019. The report addresses the termination of a definitive material agreement and references the company's financial results for the quarter ended June 30, 2019, which were announced on August 13, 2019.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the period ended June 30, 2019. These figures are incorporated by reference from a press release (Exhibit 99.1) which is not included in the provided text.
Regarding the terminated agreement with Ahon Pharmaceutical Co., Ltd.:
- Upfront payment received: $500,000.
- Unpaid milestone payment: $4.5 million (due upon regulatory clearance or July 1, 2019).
- Potential future milestones: Up to $27.5 million.
- Potential royalties: Approximately 10% on net sales in licensed territories.
Material Changes
On August 12, 2019, Diamedica Therapeutics Inc. terminated its license and collaboration agreement with Ahon Pharmaceutical Co., Ltd. due to non-payment of the $4.5 million milestone. As a result of this termination, the Company regained worldwide rights to develop and commercialize DM199 for acute ischemic stroke, including the territories previously licensed to Ahon Pharma (mainland China, Taiwan, Hong Kong S.A.R., and Macau S.A.R.).
Outlook, Risks, and Management Commentary
The termination of the agreement was the result of an inability to agree on mutually acceptable revised terms following extensive good faith discussions. The filing notes that the Company has regained control of the DM199 asset globally. No specific forward-looking guidance or risk factors beyond the context of the agreement termination are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific financial results for the quarter ended June 30, 2019, by reviewing the attached press release (Exhibit 99.1) referenced in Item 2.02.
- Confirm the current cash position and liquidity status of the Company following the termination of the Ahon Pharma agreement.
- Assess the Company's immediate plans and capital requirements for the global development of DM199 now that worldwide rights have been regained.
- Review any potential legal or financial recourse regarding the unpaid $4.5 million milestone.